Abstract
Drug regulatory agencies are increasingly pressed by the challenge of finding the appropriate balance between the need for rapid access to new drugs and the need to ensure comprehensive data on their benefits and risks. This dilemma is not new, but has been made more prominent by recent high-profile drug withdrawals and conflicting demands, including the need to improve the efficiency of drug development on one hand, and the need to avoid exposing patients to unnecessary risks or possibly ineffective treatments on the other. Here, we summarize the current demands by stakeholders and the scientific and regulatory issues at stake, describe existing and emerging regulatory approaches, and speculate on future directions, such as evolution of the current regulatory model from a one-off marketing authorization to a life-cycle approach.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ross, D. B. The FDA and the case of Ketek. N. Engl. J. Med. 356, 1601–1604 (2007).
Garattini, S. & Bertele, V. How can we regulate medicines better? BMJ 335, 803–805 (2007).
Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457–2471 (2007).
Carpenter, D., Zucker, E. J. & Avorn, J. Drug-review deadlines and safety problems. N. Engl. J. Med. 358, 1354–1361 (2008).
Barbui, C. & Garattini S. Regulatory policies on medicines for psychiatric disorders: is Europe on target? Br. J. Psychiatry 190, 91–93 (2007).
Van Luijn, J. C., Gribnau, F. W. & Leufkens, H. G. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br. J. Clin. Pharmacol. 63, 159–162 (2006).
Kaplan, W. & Laing, R. Priority Medicines for Europe and the World 1–154 (WHO, Geneva, 2004).
Pignatti, F. et al. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome. Eur. J. Clin. Pharmacol. 58, 573–80 (2002).
Garattini, S. & Bertele, V. New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable. BMJ 323, 341 (2001).
EMEA. The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future 1–68 (EMEA, London, 2005).
Kinsley, M. Why Science Can't Save the GOP. Time (New York), 24 (10 Dec 2007).
Cooksey, D. A Review of UK Health Research Funding. 1–127 (Her Majesty's Stationery Office, London, 2006).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
Avorn, J. Paying for drug approvals — who's using whom? N. Engl. J. Med. 356, 1697–1700 (2007).
FDA. Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies. Docket No. 2003N-0170. FDA web site [online] (2004).
Finkelstein, J. B. Accelerated approval regulations may need overhaul, panel suggests. J. Natl Cancer Inst. 97, 1802–1804 (2005).
FDA. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products. FDA web site [online] (2004).
FDA. FDA's Critical Path Initiative — Science Enhancing the Health and Well-Being of All Americans. FDA web site [online] (2007).
IMI. The Innovative Medicines Initiative. IMI web site [online] (2007).
[No authors listed]. Preliminary report: effect of encainide and flacainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. 321, 406–412 (1989).
Hughes, B. An audience with Clifford Rosen. Nature Rev. Drug Discov. 7, 382 (2008).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Cleland, J. G. & Atkin, S. L. Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet 370, 1103–1104 (2007).
Opar, A. Novel diabetes drugs to face higher hurdles? Nature Rev. Drug Discov. 6, 687–688 (2007).
Dagher, R., Johnson, J., Williams, G., Keegan, P. & Pazdur, R. Accelerated approval of oncology products: a decade of experience. J. Natl Cancer Inst. 96, 1500–1509 (2004).
EMEA. Committee for Medicinal Products for Human Use Summary of Positive Opinion for Tyverb. EMEA web site [online] (2008).
Kramer, J. A., Sagartz, J. E. & Morris, D. L. The application of discovery technology and pathology towards the design of safer pharmaceutical lead candidates. Nature Rev. Drug Discov. 6, 636–649 (2007).
The Medicines in Europe Forum, HAI Europe & The ISDB. Open letter to EC President Barroso 10 October 2007. European Commission web site [online] (2007).
Joshi, G. P., Gertler, R. & Fricker, R. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth. Analg. 105, 1793–1804 (2007).
Park, B. K., Pirmohamed, M. & Kitteringham, N. R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969–988 (1998).
Schultz, W. B. Bolstering the FDA's drug-safety authority. N. Engl. J. Med. 357, 2217–2219 (2007).
Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360–364 (2004).
Delany, M. Accelerated approval: where are we now? Res. Initiative Treat. Action Summer, 18–22 (2002).
Garattini, S. & Bertele, V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370, 1875–1877 (2007).
EMEA. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement Commission Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004. EMEA web site [online] (2006).
FDA. Fast Track, Accelerated Approval and Priority Review. Acclerating Availability of New Drugs for Patients with Serious Diseases. FDA web site [online] (2006).
Committee on the Assessment of the US Drug Safety System & Board on Population Health and Public Health Practice. The Future of Drug Safety. Promoting and Protecting the Health of the Public 1–348 (eds Baciu, A., Stratton, K. & Burke, S. P.) (The National Academies Press, Washington, DC, 2007).
EMEA & HMA. European Risk Management Strategy: 2008–2009 Work Programme Adopted. EMEA web site [online] (2007).
EMEA. Committee for Medicinal Products for Human Use (CHMP). Guideline on Risk Management Systems for Medicinal Products for Human Use. EMEA web site [online] (2005).
Sheiner, L. B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275–291 (1997).
McClellan, M. Drug safety reform at the FDA — pendulum swing of systematic improvement? N. Engl. J. Med. 356, 1700–1702 (2007).
Avorn, J. In defense of pharmacoepidemiology — embracing the yin and yang of drug research. N. Engl. J. Med. 357, 2219–2221 (2007).
EMEA. Executive Summary Report on EMEA Meeting with Interested Parties and Research Centres on ENCEPP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance). 28 June 2007, EMEA. EMEA web site [online] (2007).
Van Merkerk, R. O. & Boon, W. P. C. Industry strategies on theranostics: need for structural alignment. Drug Discov. World 8, 61–70 (2007).
Wang, S. J., O'Neill, R. T. & Hung, H. M. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat. 6, 227–244 (2007).
Vandenbroecke, J. P. Observational research, randomised trials, and two views of medical science. PLoS Med. 5, e67 (2008).
Kirsch, I. et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5, e45 (2008).
Editorial. UK's NICE to offer scientific advice to pharma companies. Regul. Aff. J. 19, 412–413 (2008).
European network for Health Technology Assessment (EUnetHTA). HTA Core Model for Medical and Surgical Interventions. First Public Draft (Revised) 11th July 2007. EUnetHTA web site [online] (2007).
[No author listed]. Commission's guidance on protecting new indications. Scrip 3319, 2 (2007).
EMEA. European Public Assessment Report (EPAR) Sutent. EPAR Summary for the Public. EMEA web site [online] (2007).
The British Heart Foundation (BHF). Incidence of Myocardial Infarction. BHF Statistics web site [online] (2007).
Author information
Authors and Affiliations
Corresponding author
Related links
Rights and permissions
About this article
Cite this article
Eichler, HG., Pignatti, F., Flamion, B. et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 7, 818–826 (2008). https://doi.org/10.1038/nrd2664
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2664
This article is cited by
-
Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions
Pharmaceutical Medicine (2022)
-
Uptake of new antidiabetic medicines in 11 European countries
BMC Endocrine Disorders (2021)
-
A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics
The European Journal of Health Economics (2020)
-
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
Cardio-Oncology (2018)
-
Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms
Archives of Toxicology (2018)